Abstract / Summary
ObjectiveSodium-glucose cotransporter 2 inhibitors are widely used in the management of diabetes mellitus and have demonstrated substantial cardiovascular and renal protective effects, particularly in patients with heart failure. However, their impact on cardiovascular outcomes in patients with chronic obstructive pulmonary disease remains insufficiently characterized.MethodsWe conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with chronic obstructive pulmonary disease. The primary outcome was the composite cardiovascular outcome (defined as cardiovascular mortality and total hospitalization for heart failure). Secondary outcomes included all-cause mortality, cardiovascular death, hospitalization for heart failure, and adverse events.ResultsThree randomized controlled trials involving 1986 patients with chronic obstructive pulmonary disease were included; in total, 1113 patients received sodium-glucose cotransporter 2 inhibitors treatment and 873 received placebo. Compared with the placebo, sodium-glucose cotransporter 2 inhibitors significantly reduced the risk of the composite cardiovascular outcome (risk ratio, 0.76; 95% confidence interval: 0.65-0.87; p < 0.001) and hospitalization for heart failure (risk ratio, 0.69; 95% confidence interval: 0.58-0.83; p < 0.001). Although not statistically significant, trends toward reduced all-cause mortality (risk ratio, 0.89; 95% confidence interval: 0.73-1.08; p = 0.23) and cardiovascular death (risk ratio, 0.96; 95% confidence interval: 0.74-1.24; p = 0.73) were observed. The incidence of adverse events was comparable between the two groups.ConclusionsThe use of sodium-glucose cotransporter 2 inhibitors is associated with a reduced risk of composite cardiovascular outcomes and hospitalization for heart failure in patients with chronic obstructive pulmonary disease, without an increased risk of adverse events. However, given the limited number of available trials, these findings should be interpreted with caution, and further large-scale studies are warranted.PROSPERO registration number: CRD42024545310.
Primary Source
The Journal of international medical research
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.